Influence of pretreatment with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APB) on organ uptake of 211At and 125I-labeled amidobisphosphonates in mice

Nucl Med Biol. 1999 Oct;26(7):791-4. doi: 10.1016/s0969-8051(99)00047-5.


To minimize nontarget organ uptake in animals receiving radiolabeled amidobisphosphonates, the influence of pretreatment with cold 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APB, pamidronate) was studied. Three groups of animals were given pure 3-[125I]iodobenzamide-N-3-hydroxypropylidene-3,3-bisphosphonate (IBPB) and 3-[211At]astatobenzamide-N-3-hydroxypropylidene-3,3-bisphosphonate (ABPB) (control); co-injection of APB and IBPB/ABPB; and 1 h preinjection of APB followed by IBPB/ABPB, respectively. A significant reduction of uptake in normal tissue was observed, whereas the bone uptake remained constant at 35-50%ID/g tissue. This study suggests that co- or preinjection of pamidronate may reduce the normal organ radiation doses when using these radiohalogenated bisphosphonates for endoradiotherapeutic procedures.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Astatine* / chemistry
  • Bone and Bones / metabolism
  • Diphosphonates / chemical synthesis
  • Diphosphonates / pharmacokinetics*
  • Diphosphonates / pharmacology*
  • Femur / metabolism
  • Iodine Radioisotopes / chemistry
  • Isotope Labeling
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Organ Specificity
  • Pamidronate
  • Radiopharmaceuticals / chemical synthesis
  • Radiopharmaceuticals / pharmacokinetics*
  • Tissue Distribution


  • 3-astatobenzamido-N-3-hydroxypropylidene-3,3-bisphosphonate
  • 3-iodobenzamido-N-3-hydroxypropylidene-3,3-bisphosphonate
  • Antineoplastic Agents
  • Diphosphonates
  • Iodine Radioisotopes
  • Radiopharmaceuticals
  • Pamidronate
  • Astatine